Patricia Hopson, DO
Endocrinology, Diabetes & Metabolism · Corvallis, ORNPI 1508852252
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $146,671 of the $165,555 with a category attached, or 88.6%. 13 manufacturers reported payments, led by Lilly USA, LLC at 58.0% of the total. Reporting peaked in 2019 at $58,473 and has fallen 98.4% since, to $931 in 2025. Among endocrinology, diabetes & metabolism clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $518.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$96K
- Novo Nordisk$64K
- Boehringer Ingelheim$3K
- Eli Lilly$2K
- Abbott$459
- Sanofi Pasteur Inc.$106
- plus $302 from 7 others
Across 19 payments — averaging $48,527 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$918K
- Eli Lilly Export S.A. Puerto Rico Branch$4K
What the payments were for
- Consulting fees$5,5253%
- Speaking & faculty fees$146,67189%
- Travel & lodging$7,4955%
- Food & beverage$5,8314%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 182 | $95,990 |
| Novo Nordisk | 85 | $63,991 |
| Boehringer Ingelheim | 8 | $3,045 |
| Eli Lilly | 20 | $1,662 |
| Abbott | 13 | $459 |
| Sanofi Pasteur Inc. | 1 | $106 |
| Amgen(2 entities) | 2 | $96 |
| Bayer | 1 | $80 |
| Tandem Diabetes Care, Inc. | 3 | $47 |
| Sequel Med Tech, LLC | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$47,858
- MOUNJARO$37,059
- Ozempic$26,052
- RYBELSUS$23,969
- JARDIANCE$8,133
- Tresiba$6,664
- Xultophy 100/3.6$3,075
- FREESTYLE LIBRE 3$108
- BEYFORTUS$106
How this compares
$165,555 in reported general payments places this provider in the 90th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 222 | $277,231 |
| MounjaroTirzepatide | 178 | $215,921 |
| JardianceEmpagliflozin | 204 | $184,349 |
| TrulicityDulaglutide | 131 | $138,148 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $41,713 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $40,324 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $36,896 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $26,547 |
| Humalog Kwikpen U-100Insulin Lispro | 80 | $24,532 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $23,199 |
| FarxigaDapagliflozin Propanediol | 15 | $19,262 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $17,005 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $16,659 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $16,328 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $15,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $95,990 | $371,040408 claims |
| Novo NordiskOzempic, Tresiba | $63,991 | $286,555235 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $3,045 | $210,896219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Corvallis
- Judy ShihCorvallis$1K
- Timothy ArakawaCorvallis$536
- Steven CathcartCorvallis$450
- Jonathan BennionCorvallis$445
- Katy BrownCorvallis$303
- Michael McClungPortland$1.3M
- Maria FleseriuPortland$464K
- James NeifingPortland$311K
- Rodica BusuiPortland$255K
- Jonathan PurnellPortland$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.